Literature DB >> 16607377

hMLH1 and MGMT inactivation as a mechanism of tumorigenesis in monoclonal gammopathies.

Paloma Martin1, Almudena Santón, Mónica García-Cosio, Carmen Bellas.   

Abstract

Monoclonal gammopathies are a group of disorders characterized by clonal proliferation and accumulation of immunoglobulin-producing plasma cells. Multiple myeloma and monoclonal gammopathy of undetermined significance are the most common monoclonal gammopathies; the two comprise a spectrum of disorders, ranging from a relatively benign disease, monoclonal gammopathy of undetermined significance, to a malignant disease, multiple myeloma. Aberrant promoter methylation represents a primary mechanism of gene silencing during tumorigenesis. DNA repair systems act to maintain genome integrity in the presence of replication errors, environmental insults, and the cumulative effects of aging. The methylation patterns of two genes implicated in DNA repair, O6 methylguanine DNA methyl-transferase (MGMT) and human mutL homologue1 (hMLH1) have been detected in various solid tumours. With the purpose of studying the gene silencing of MGMT and hMLH1 in plasma cell disorders, we investigated the methylation status and expression of both genes in: 29 cases of multiple myeloma; one case of plasma cell leukaemia; 13 cases of monoclonal gammopathy of undetermined significance; and two cases of polyclonal plasmacytosis, using methylation-specific polymerase-chain reaction and immunohistochemical techniques. Methylation frequencies for MGMT were 23% in multiple myeloma and 8% in monoclonal gammopathy of undetermined significance. It was 10% for hMLH1 in multiple myeloma. None of the patients diagnosed with monoclonal gammopathy of undetermined significance had hMLH1 hypermethylated. In addition, 50% of myeloma cases had a loss of hMLH1 expression, whereas silencing of MGMT was observed in 43% of myeloma and 36% of samples with monoclonal gammopathy of undetermined significance. This study indicates that repair pathway defects play a role in the pathogenesis and evolution of monoclonal gammopathies, and suggests that inactivation of hMLH1 could be implicated in multiple myeloma tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16607377     DOI: 10.1038/modpathol.3800590

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  5 in total

Review 1.  DNA repair pathways in human multiple myeloma: role in oncogenesis and potential targets for treatment.

Authors:  Claire Gourzones-Dmitriev; Alboukadel Kassambara; Surinder Sahota; Thierry Rème; Jérôme Moreaux; Pascal Bourquard; Dirk Hose; Philippe Pasero; Angelos Constantinou; Bernard Klein
Journal:  Cell Cycle       Date:  2013-08-09       Impact factor: 4.534

Review 2.  The Role of DNA Repair in Genomic Instability of Multiple Myeloma.

Authors:  Jana Yasser Hafez Ali; Amira Mohammed Fitieh; Ismail Hassan Ismail
Journal:  Int J Mol Sci       Date:  2022-05-19       Impact factor: 6.208

3.  Promoter methylation status of MGMT, hMSH2, and hMLH1 and its relationship to corresponding protein expression and TP53 mutations in human esophageal squamous cell carcinoma.

Authors:  Yaoyao Su; Lihong Yin; Ran Liu; Jingyi Sheng; Miao Yang; Yi Wang; Enchun Pan; Wei Guo; Yuepu Pu; Juan Zhang; Geyu Liang
Journal:  Med Oncol       Date:  2013-12-24       Impact factor: 3.064

Review 4.  O6-Methylguanine-DNA methyltransferase protein expression by immunohistochemistry in brain and non-brain systemic tumours: systematic review and meta-analysis of correlation with methylation-specific polymerase chain reaction.

Authors:  Marta Brell; Javier Ibáñez; Avelina Tortosa
Journal:  BMC Cancer       Date:  2011-01-26       Impact factor: 4.430

5.  Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wide copy number array analysis.

Authors:  Martin Granzow; Ute Hegenbart; Katrin Hinderhofer; Dirk Hose; Anja Seckinger; Tilmann Bochtler; Kari Hemminki; Hartmut Goldschmidt; Stefan O Schönland; Anna Jauch
Journal:  Haematologica       Date:  2017-03-24       Impact factor: 9.941

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.